|
1
|
Marsolier J, Prompsy P, Durand A, Lyne AM, Landragin C, Trouchet A, Bento ST, Eisele A, Foulon S, Baudre L, Grosselin K, Bohec M, Baulande S, Dahmani A, Sourd L, Letouzé E, Salomon AV, Marangoni E, Perié L, Vallot C. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat Genet 2022; 54:459-468. [PMID: 35410383 PMCID: PMC7612638 DOI: 10.1038/s41588-022-01047-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 03/04/2022] [Indexed: 12/11/2022]
Abstract
The persistence of cancer cells resistant to therapy remains a major clinical challenge. In triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence risk among breast cancer subtypes. The drug-tolerant state seems largely defined by nongenetic features, but the underlying mechanisms are poorly understood. Here, by monitoring epigenomes, transcriptomes and lineages with single-cell resolution, we show that the repressive histone mark H3K27me3 (trimethylation of histone H3 at lysine 27) regulates cell fate at the onset of chemotherapy. We report that a persister expression program is primed with both H3K4me3 (trimethylation of histone H3 at lysine 4) and H3K27me3 in unchallenged cells, with H3K27me3 being the lock to its transcriptional activation. We further demonstrate that depleting H3K27me3 enhances the potential of cancer cells to tolerate chemotherapy. Conversely, preventing H3K27me3 demethylation simultaneously to chemotherapy inhibits the transition to a drug-tolerant state, and delays tumor recurrence in vivo. Our results highlight how chromatin landscapes shape the potential of cancer cells to respond to initial therapy.
Collapse
Affiliation(s)
- Justine Marsolier
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Pacôme Prompsy
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Adeline Durand
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Anne-Marie Lyne
- CNRS UMR168, Institut Curie, PSL University, Sorbonne University, Paris, France
| | - Camille Landragin
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Amandine Trouchet
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Single Cell Initiative, Institut Curie, PSL University, Paris, France
| | | | - Almut Eisele
- CNRS UMR168, Institut Curie, PSL University, Sorbonne University, Paris, France
| | - Sophie Foulon
- CNRS UMR8231, ESPCI Paris, PSL University, Paris, France
| | - Léa Baudre
- CNRS UMR3244, Institut Curie, PSL University, Paris, France,Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Kevin Grosselin
- CNRS UMR8231, ESPCI Paris, PSL University, Paris, France,HiFiBio SAS, Paris, France,Current Affiliation: Broad Institute of MIT and Harvard, Cambridge MA, USA
| | - Mylène Bohec
- Single Cell Initiative, Institut Curie, PSL University, Paris, France,Genomics of Excellence (ICGex) Platform, Institut Curie, PSL University, Paris, France
| | - Sylvain Baulande
- Single Cell Initiative, Institut Curie, PSL University, Paris, France,Genomics of Excellence (ICGex) Platform, Institut Curie, PSL University, Paris, France
| | - Ahmed Dahmani
- Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Laura Sourd
- Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Eric Letouzé
- Functional Genomics of Solid Tumors laboratory, Centre de Recherche des Cordeliers, Sorbonne University, Inserm, USPC, Paris Descartes University, Paris Diderot University, Paris, France
| | - Anne-Vincent Salomon
- Pathology-Genetics-Immunology Department, Institut Curie, PSL Research University, Paris, France,INSERM U934, Institut Curie, PSL Research University, Paris, France
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, PSL University, Paris, France
| | - Leïla Perié
- CNRS UMR168, Institut Curie, PSL University, Sorbonne University, Paris, France
| | - Céline Vallot
- CNRS UMR3244, Institut Curie, PSL University, Paris, France. .,Translational Research Department, Institut Curie, PSL University, Paris, France.
| |
Collapse
|
|
2
|
Gérard A, Woolfe A, Mottet G, Reichen M, Castrillon C, Menrath V, Ellouze S, Poitou A, Doineau R, Briseno-Roa L, Canales-Herrerias P, Mary P, Rose G, Ortega C, Delincé M, Essono S, Jia B, Iannascoli B, Richard-Le Goff O, Kumar R, Stewart SN, Pousse Y, Shen B, Grosselin K, Saudemont B, Sautel-Caillé A, Godina A, McNamara S, Eyer K, Millot GA, Baudry J, England P, Nizak C, Jensen A, Griffiths AD, Bruhns P, Brenan C. Author Correction: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nat Biotechnol 2020; 38:756. [PMID: 32444853 DOI: 10.1038/s41587-020-0563-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
| | | | - Guillaume Mottet
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France
| | | | - Carlos Castrillon
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.,École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.,Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | | | | | | | - Raphaël Doineau
- HiFiBiO Therapeutics SAS, Paris, France.,École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.,Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.,Institute for Integrative Nanosciences, Leibniz IFW Dresden e.V., Dresden, Germany
| | - Luis Briseno-Roa
- HiFiBiO Therapeutics SAS, Paris, France.,Medetia Pharma, Institut Imagine, Paris, France
| | - Pablo Canales-Herrerias
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.,École Doctorale Frontières du Vivant (FdV), Centre de Recherches Interdisciplinaires, Paris, France.,Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | | | | | | | | | | | - Bin Jia
- Pfizer, Cambridge, MA, USA.,Abbvie Bioresearch Center, Worcester, MA, USA
| | - Bruno Iannascoli
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France
| | - Odile Richard-Le Goff
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France
| | | | | | | | | | - Kevin Grosselin
- HiFiBiO Therapeutics SAS, Paris, France.,Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | - Baptiste Saudemont
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.,Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | - Antoine Sautel-Caillé
- Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | - Alexei Godina
- Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | | | - Klaus Eyer
- Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.,Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, D-CHAB, ETH Zürich, Zurich, Switzerland
| | - Gaël A Millot
- Institut Pasteur, Hub Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Paris, France
| | - Jean Baudry
- Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | - Patrick England
- Plateforme de Biophysique Moléculaire, Institut Pasteur, CNRS UMR3528, Paris, France.,Centre d'Innovation et de Technologie, Plateforme de Biophysique des Macromolecules et de leurs Interactions, Institut Pasteur, Paris, France
| | - Clément Nizak
- Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France
| | - Allan Jensen
- HiFiBiO Therapeutics SAS, Paris, France.,Lundbeck A/S, Valby, Denmark
| | - Andrew D Griffiths
- Laboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
| | - Pierre Bruhns
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
| | - Colin Brenan
- HiFiBiO Therapeutics SAS, Paris, France. .,HiFiBiO Therapeutics Inc., Cambridge, MA, USA. .,1CellBiO Inc., Watertown, MA, USA.
| |
Collapse
|